Increased expression of fibroblast growth factor 13 (FGF13) in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.

Fibroblast growth factor homologous factors (FHFs) belong to the fibroblast growth factor (FGF) superfamily, which plays an important role in prostate cancer (PCa). Mining of public database suggests that FGF13 (FHF2) mRNA expression is altered in over 30% of PCa cases.

This study examined the FGF13 expression pattern in human PCa specimens and evaluated its potential as a biomarker for patient outcome after radical prostatectomy (RP). Immunohistochemistry (IHC) showed that FGF13 was detectable in the majority of human PCa samples, and FGF13 IHC scores were higher in high-grade prostatic intraepithelial neoplasia, in primary PCa, and in metastatic PCa than in benign prostatic tissue. There was a significant association between high cytoplasmic FGF13 staining and a risk of biochemical recurrence (BCR) after RP. This was also evident in the intermediate to high risk patient groups. In contrast, positive nuclear FGF13 staining along with low cytoplasmic FGF13 group showed a decreased BCR risk. Multivariate regression analysis indicated that high cytoplasmic FGF13 staining was associated with BCR and that this could serve as an independent prognostic marker in PCa. Several PCa cell lines showed increased FGF13 expression at the mRNA and protein levels compared to the immortalized prostate epithelial cell line PNT1a. Analysis of co-labelled cells suggested a possible interaction of FGF13 with α-tubulin and the voltage-gated sodium channel proteins (NaV s/VGSCs). Our data indicates that, for PCa patients after RP, FGF13 serves as a potential novel prognostic marker that improves prediction of BCR-free survival, in particular if combined with other clinical parameters. This article is protected by copyright. All rights reserved.

International journal of cancer. Journal international du cancer. 2016 Feb 17 [Epub ahead of print]

Lan Yu, Mervi Toriseva, Miikka Tuomala, Heikki Seikkula, Teresa Elo, Johanna Tuomela, Markku Kallajoki, Tuomas Mirtti, Pekka Taimen, Peter J Boström, Kalle Alanen, Martti Nurmi, Matthias Nees, Pirkko Härkönen

Department of Cell Biology and Anatomy, Institute of Biomedicine, University of Turku, Finland. , Department of Cell Biology and Anatomy, Institute of Biomedicine, University of Turku, Finland. , Department of Cell Biology and Anatomy, Institute of Biomedicine, University of Turku, Finland. , Department of Urology, Turku University Hospital, Finland. , Institute of Biotechnology, University of Helsinki, Finland. , Department of Cell Biology and Anatomy, Institute of Biomedicine, University of Turku, Finland. , Department of Pathology, University of Turku, Finland. , Department of Pathology, Helsinki University Hospital (HUSLAB) and Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Finland. , Department of Pathology, University of Turku, Finland. , Department of Pathology, University of Turku, Finland. , Department of Pathology, University of Turku, Finland. , Department of Pathology, University of Turku, Finland. , Department of Cell Biology and Anatomy, Institute of Biomedicine, University of Turku, Finland. , Department of Cell Biology and Anatomy, Institute of Biomedicine, University of Turku, Finland.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe